Therapeutic effect of a 2-10mg once yearly dosage regimen is made plausible by an example showing clinical effect of dosage regimens of 0.25, 0.50 and 1mg per three months, 2.0 mg every six months and 4.0 mg once a year. For the purpose of the problem-solution approach, two documents describing a treatment of diseases which have the same underlying cause (bone resorption) do not necessarily have the same purpose. Indirect infringement of a Swiss-type claim is not possible.

A full summary of this case has been published on Kluwer IP Law.


________________________

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.


Kluwer Arbitration
This page as PDF